Amendments for: 172-2020-2021-Q4-969474

Agreement Value: $198,000.00
Agreement: AI powered design of stem cell therapy for degenerative muscle diseases (969474). Mar 29, 2021 - Jun 30, 2024
Description:

Stem cells harbour tremendous potential for tissue regeneration after injury or in the face of chronic/degenerative disease. Yet, clinical application of stem cell therapies for muscle degenerative diseases has been limited due in part to the complexities of manipulating or augmenting stem cell systems in vivo. Designing optimal stem cell therapies is therefore extremely challenging because testing of every design is highly time-consuming and costly. In silico design using machine learning models can provide a high performance alternative solution. The overall objective of this Project is the development of novel AI-driven methodologies for optimal cell therapy design. This will be achieved by accurately predicting the outcomes of targeted perturbations of a stem cell system based on advanced single-cell genomic data. Researchers will collect publicly available skeletal muscle-relevant single-cell data and in-house cell data from the Ottawa Hospital Research Institute, as well as from the NRC’s Disruptive Technology Solutions for Cell and Gene Therapy Program. The AI-methodologies and simulation models developed in this Project will help to better understand the mechanisms of how stem cells differentiate to specific cell types with desired properties, speeding up the optimal strategy for selection while reducing the costs and facilitating the safe and efficient stem cell therapy.
The outcome of this Project will provide an efficient and robust tool for optimal stem cell therapy selection.

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Organization: National Research Council Canada
Recipient: Ottawa Hospital Research Institute (Not-for-profit organization or charity)
Location: Ottawa, Ontario, CA K1Y 4E9
Type: Grant
Additional Information:

This agreement has been amended 1 time(s). The end date of this agreement has been modified by 459 days.

Federal Riding Name: Ottawa Centre (35075)
Program Name: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code: 541710

Agreement Value:
Agreement: AI powered design of stem cell therapy for degenerative muscle diseases - Jun 30, 2024
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:

This agreement has been amended 1 time(s). The end date of this agreement has been modified by 459 days.

NAICS Code: 541710

Agreement Value: $198,000.00
Agreement: Artificial intelligence (AI) powered design of stem cell therapy for degenerative muscle diseases (969474). Mar 29, 2021 - Mar 28, 2023
Description:

Stem cells harbour tremendous potential for tissue regeneration after injury or in the face of chronic/degenerative disease. Yet, clinical application of stem cell therapies for muscle degenerative diseases has been limited due in part to the complexities of manipulating or augmenting stem cell systems in vivo. Designing optimal stem cell therapies is therefore extremely challenging because testing of every design is highly time-consuming and costly. In silico design using machine learning models can provide a high performance alternative solution. The overall objective of this Project is the development of novel AI-driven methodologies for optimal cell therapy design. This will be achieved by accurately predicting the outcomes of targeted perturbations of a stem cell system based on advanced single-cell genomic data. Researchers will collect publicly available skeletal muscle-relevant single-cell data and in-house cell data from the Ottawa Hospital Research Institute, as well as from the NRC’s Disruptive Technology Solutions for Cell and Gene Therapy Program. The AI-methodologies and simulation models developed in this Project will help to better understand the mechanisms of how stem cells differentiate to specific cell types with desired properties, speeding up the optimal strategy for selection while reducing the costs and facilitating the safe and efficient stem cell therapy.
The outcome of this Project will provide an efficient and robust tool for optimal stem cell therapy selection.

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Organization: National Research Council Canada
Recipient: Ottawa Hospital Research Institute (Not-for-profit organization or charity)
Location: Ottawa, Ontario, CA K1Y 4E9
Type: Grant
Federal Riding Name: Ottawa Centre (35075)
Program Name: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code: 541710 - R&D in the physical, engineering and life sciences